parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in astrocytes (514 nCPM)	1.00
chemistry Open Targets	hard to drug	0.40
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 41	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 5203

ETNPPL in dopamine neurons, braak+0.13 (p 0.735) → +0.24 (p 0.530)receipt 5212
ETNPPL in astrocytes, braak+0.10 (p 0.807) → -0.06 (p 0.873)receipt 5211

receipt 5212: ETNPPL in dopamine neurons, braak

power: full sample +0.24 (p 0.328, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.360, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.26 (p 0.306, n 18). could be the mix.
skeptic: leave-one-out range +0.18 to +0.44, sign flips 0; without severely affected donors +0.24 (p 0.328, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ETNPPL in dopamine neurons.

case closed: nothing better to follow up.

receipt 5211: ETNPPL in astrocytes, braak

power: full sample -0.03 (p 0.922, n 18), 95% CI -0.49 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.01 (p 0.969, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.11 (p 0.658, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.08, sign flips 10; without severely affected donors -0.03 (p 0.922, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ETNPPL in astrocytes.

case closed: nothing better to follow up.

loading the receipts